Reduced Dosing Frequency With Tralokinumab Provides Sustained Improvements in Symptoms and Quality of Life Up to 1 Year in Adults With Moderate-to-Severe AD. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 10, n. 2, p. s731, 2026. DOI: 10.25251/26swpe94. Disponível em: https://skin.dermsquared.com/skin/article/view/4038. Acesso em: 30 apr. 2026.